Abiraterone shows promise in prostate cancer fight, Dimebon for Alzheimer’s

The World

A 21-patient study has shown that the drug abiraterone can stop the testosterone that feeds prostate cancer. A larger international clinical trial is underway to test the drug before it can be deemed a “miracle drug.” Also, Dimebon, once used as an antihistamine, has been found to improve cognitive abilities for Alzheimer’s patients, though researchers aren’t yet sure how. Guests: Dr. Anthony D’Amico, professor and chief of Genitourinary Radiation Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, and Dr. Samuel Gandy, Associate Director of the Mount Sinai Alzheimer’s Disease Research Center, and Chair of the National Medical and Scientific Advisory Council of the Alzheimer’s Association

Will you support The World with a monthly donation?

Every day, reporters and producers at The World are hard at work bringing you human-centered news from across the globe. But we can’t do it without you. We need your support to ensure we can continue this work for another year.

Make a gift today, and you’ll help us unlock a matching gift of $67,000!